US Food and Drug Administration According to agency commissioner Dr. Marty McCurry and Dr. Vinai Prasad, who heads the division overseeing vaccines and gene therapy, they plan to use artificial intelligence when deciding whether to approve new drugs and devices, one of the few top priorities: new drugs and devices.
An overview of their new plans Jama Networkthey said another initiative includes a review of chemicals and other “ingredients” found in American foods, rather than foods from other developed countries. And they said the agency would like to expand the final stage of its drug or medical device approval decision to just a few weeks. Operation warp speed During the symbiotic pandemic, when workers competed to curb the spiral death count.
“FFA focuses on providing faster treatments and meaningful treatments to patients, especially those suffering from neglected rare diseases, healthy foods for children, and a common-sense approach to rebuilding public trust,” they write.
The new roadmap is part of the Trump administration's efforts to smooth the path of major industries with a variety of initiatives aimed at acquiring products in pharmacies and shelves, reports New York Times.
However, some aspects of the proposal were greeted with the idea that artificial intelligence, in particular, can range from painstaking work to consider applications that companies submit when seeking approval for drugs or risky medical devices, to shear challenges for months or years.
“We don't want to reject a review of speeding at the FDA,” said Stephen Holland, an attorney who previously advised the House Committee on Energy and Commerce in Healthcare. “I think there's a great potential here, but I haven't seen the beef yet.”
The major AI rollout continues closely with the release of a report by Robert F. Kennedy JR's Health Secretary Maha Committee (to make America healthy again), it turns out to be a reference to scientific research clearly manufactured by the Artificial Intelligence Program.
In some cases, FDA officials have proposed accelerated major drug approval by requesting only one major study of patients rather than two. This is a practice that institutions have used in recent years. The pandemic has provided precedents to speed up the process.
“I believe this clearly indicates that quick or immediate review is possible,” writes McCurry and Prasad.
However, the Netherlands noted that during the pandemic, many staff members were transferred from routine mandates, including overseas testing of food and drug facilities, and were reassigned to speed up reviews of important Covid products.
The agents also had better staff. In recent months, the FDA has eliminated nearly 2,000 employees and reduced its workforce from around 10,000 to 8,000.
Last week, the agency introduced Elsa, a large-scale language model of artificial intelligence similar to ChatGpt. The FDA said it could be used to prioritize food or drug facilities to be tested, to describe side effects in drug safety summaries, and to perform other basic product review tasks.
Officials wrote that AI retains its promise to “fundamentally increase efficiency” when examining up to 500,000 pages submitted for approval decisions.
Current and former health officials said AI tools are useful, but far from being transformative. One means that some Rote data analysis tasks cannot be performed because it limits the number of characters that a model can review. The results need to be checked carefully and so far it has not saved time.
Staff said the model was hallucinating or creating misinformation. Employees can summarise texts into the ELSA model and ask them to act as experts in a particular medical field.
Makary said the AI model is not trained with data submitted by the drug or medical device industry.
When it comes to food surveillance, McAlee and Prasad said there is a new focus on “an increasingly chemically manipulated diet.”
“About all additives,” the article states, “We need to reevaluate the balance for profit.”
The Trump administration is calling for a sharp cut in the FDA budget for the upcoming fiscal year, but the food sector is expected to receive additional funds.
Makary and Prasad write that the FDA must be “partners with the industry” while avoiding “the cozy relationships that have characterized agents in the past.”
Dr Reshma Ramachandran, Director Yale's collaboration for strictness, integrity and transparency of regulationspointed out that McCurry and Prasad are taking part in a closed door listening tour of six cities to meet the pharmaceutical industry's chief executives.
“How does this protect your agency against your comfortable relationship with the industry?” she asked.
Article from The New York Times – FDA uses AI to “furtherly increase efficiency” in drug approval (access restriction)
Find out more about the MedicalBrief archive.
RFK JR moves to ban artificial dyes in food
Top FDA boss resigns from RFK JR's “misinformation”
RFK JR threatens to ban scientists from publishing in top journals
